Which eye drop heals your cornea faster after laser surgery?

NCT ID NCT04704518

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two eye drops, Lagricel and Thealoz, to see which helps the cornea heal faster after PRK laser eye surgery. 96 adults who had PRK surgery used one of the drops four times a day for two weeks. The main goal was to measure how quickly the cornea's outer layer closed up after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

96 people

The number who actually took part.

Started

Sep 2022

Finished

Dec 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age ≥ 18 and ≤ 45 years old * Being on PRK postoperative day 1 (right eye will be evaluated for efficacy) * Presenting a PRK surgical corneal ablation surface of 5.5 to 6.0 mm * PRK corneal output ≤ 60 µm * Preoperative refraction of -1.0 to -4.5 D of myopia or myopic astigmatism (in this case, the sum of both values with a spherical equivalent no greater than -4.5 D) * Being capable of voluntarily grant a signed informed consent. * Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures. * Being willing and able to modify the required lifestyle activities. * Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study. Exclusion Criteria: * Having suffered any complications during and after PRK surgical procedure previous to inclusion in the study. * Use of mitomycin during PRK * Being subjected to PRK retreatment of previous history of any other kind of refractive surgery. * Pregnancy, breastfeeding or planning to become pregnant during the time of the study * Having participated in clinical trials within 30 days prior to signing this study's informed consent form. * Having participated previously in this study. * Diagnosis of any of the following: * Allergic, viral or bacterial conjunctivitis * Dry eye * Anterior blepharitis * Parasite infestation of ocular structures (Demodex, for example) * Previous history of ocular herpes * Previous history of ocular inflammation (such as uveitis) * Corneal or conjunctival ulcers * Glaucoma * Previous history of drug addiction within the last 2 years previous to signing this study's informed consent form. * Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date. * Previous history of any medical affliction, acute or chronic (such as Diabetes Mellitus type I/II, autoimmune diseases or HIV), that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results. * Use of medications (such as retinoic acid) that according to the investigator's criteria may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results. * Known hypersensitivity to any of the components of the products used in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corneal de-epithelialization are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aris Vision Institute de Guadalajara, S. C.

    Guadalajara, Jalisco, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.